NEC OncoImmunity AS
Richard Stratford is a seasoned professional in the life sciences sector, currently serving as Co-founder and Advisor at NEC OncoImmunity AS since August 2019, and previously holding the position of Chief Executive Officer at OncoImmunity AS from January 2014 to July 2019. Richard has extensive experience in business development, having worked as an Independent business development consultant at Singleøen Mekaniske Verksted AS from January 2010 to December 2013, where services included market analysis and IP management. Prior roles also include Head of Business Development at LingVitae and Business Development Manager positions at SingVax Pte Ltd and Microscience. Richard holds a PhD in Immunology and Molecular Biology from Imperial College London and a BSc in Biochemistry and related fields from Newcastle University.
NEC OncoImmunity AS
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning software, which addresses the key gaps in the prediction of bona fide immunogenic antigens for personalized cancer immunotherapy and infectious disease vaccines. We are dedicated to developing scalable software solutions that facilitate effective patient selection for cancer immunotherapy, and identifying optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable time frame. Our growing international team (13 countries and counting!) consists of a diverse mix of data scientists, bioinformaticians, immunologists, cancer researchers, and software developers. NEC OncoImmunity AS is a subsidiary of the NEC Corporation, and is based in the Oslo Cancer Cluster buildings in Oslo, Norway.